Reversed phase free ion selective radiotracer extraction (RP-FISRE): A new tool to assess the dynamic stabilities of metal (-organic) complexes, for complex half-lives spanning six orders of magnitude
“…Dissociation kinetics of Lu-DOTATATE complex were reported by Van der Meer et al . using a similar system and an order of magnitude difference was calculated when the temperature was increased from 20 to 37 °C23. A higher dissociation rate turns into a higher concentration of dissociated 177m Lu in the mobile phase decreasing the value of the activity ratio and the quality of the elution.…”
Section: Discussionmentioning
confidence: 99%
“…While the use of the metastable 177m Lu as the parent radionuclide for 177 Lu production was proposed by De Vries and Wolterbeek22, the realization of a generator has not been demonstrated yet. In order to prove this concept, we have chosen a reversed phase chromatographic system in which 177m Lu-DOTA-(Tyr 3 )-octreotate (DOTATATE) complex (with a dissociation constant k d = 2·10 −8 s −1 at 20 °C) is retained in a tC-18 silica column23. The tC-18 silica filler has no affinity toward polar metal ions, and thus the bond ruptured 177 Lu ions can be eluted off the column using a mobile phase flow, while the 177m Lu-DOTATATE complex exhibits a very long retention time with the chosen mobile phase, and remains immobilized on the column during the experiments (shown schematically in Fig.…”
177Lu has sprung as a promising radionuclide for targeted therapy. The low soft tissue penetration of its β− emission results in very efficient energy deposition in small-size tumours. Because of this, 177Lu is used in the treatment of neuroendocrine tumours and is also clinically approved for prostate cancer therapy. In this work, we report a separation method that achieves the challenging separation of the physically and chemically identical nuclear isomers, 177mLu and 177Lu. The separation method combines the nuclear after-effects of the nuclear decay, the use of a very stable chemical complex and a chromatographic separation. Based on this separation concept, a new type of radionuclide generator has been devised, in which the parent and the daughter radionuclides are the same elements. The 177mLu/177Lu radionuclide generator provides a new production route for the therapeutic radionuclide 177Lu and can bring significant growth in the research and development of 177Lu based pharmaceuticals.
“…Dissociation kinetics of Lu-DOTATATE complex were reported by Van der Meer et al . using a similar system and an order of magnitude difference was calculated when the temperature was increased from 20 to 37 °C23. A higher dissociation rate turns into a higher concentration of dissociated 177m Lu in the mobile phase decreasing the value of the activity ratio and the quality of the elution.…”
Section: Discussionmentioning
confidence: 99%
“…While the use of the metastable 177m Lu as the parent radionuclide for 177 Lu production was proposed by De Vries and Wolterbeek22, the realization of a generator has not been demonstrated yet. In order to prove this concept, we have chosen a reversed phase chromatographic system in which 177m Lu-DOTA-(Tyr 3 )-octreotate (DOTATATE) complex (with a dissociation constant k d = 2·10 −8 s −1 at 20 °C) is retained in a tC-18 silica column23. The tC-18 silica filler has no affinity toward polar metal ions, and thus the bond ruptured 177 Lu ions can be eluted off the column using a mobile phase flow, while the 177m Lu-DOTATATE complex exhibits a very long retention time with the chosen mobile phase, and remains immobilized on the column during the experiments (shown schematically in Fig.…”
177Lu has sprung as a promising radionuclide for targeted therapy. The low soft tissue penetration of its β− emission results in very efficient energy deposition in small-size tumours. Because of this, 177Lu is used in the treatment of neuroendocrine tumours and is also clinically approved for prostate cancer therapy. In this work, we report a separation method that achieves the challenging separation of the physically and chemically identical nuclear isomers, 177mLu and 177Lu. The separation method combines the nuclear after-effects of the nuclear decay, the use of a very stable chemical complex and a chromatographic separation. Based on this separation concept, a new type of radionuclide generator has been devised, in which the parent and the daughter radionuclides are the same elements. The 177mLu/177Lu radionuclide generator provides a new production route for the therapeutic radionuclide 177Lu and can bring significant growth in the research and development of 177Lu based pharmaceuticals.
“…This leads to an estimated dissociation rate constant of 1.3*10 − 7 ± 0.3*10 − 7 s − 1 . For Lu-DOTATATE complex, a dissociation constant rate 2*10 − 8 s − 1 has been reported at pH -4.3 and 20 °C (van der Meer et al, 2013). It has also been shown that the Lu-DOTATATE complex is accompanied by the presence of short-lived unstable, mono- and di-protonated (MHL, MH 2 L) complex species (van der Meer et al, 2013).…”
Section: Discussionmentioning
confidence: 95%
“…For Lu-DOTATATE complex, a dissociation constant rate 2*10 − 8 s − 1 has been reported at pH -4.3 and 20 °C (van der Meer et al, 2013). It has also been shown that the Lu-DOTATATE complex is accompanied by the presence of short-lived unstable, mono- and di-protonated (MHL, MH 2 L) complex species (van der Meer et al, 2013). These species have a dissociation rate constant of 8*10 − 5 s − 1 (MHL) & 2*10 − 4 s − 1 (MH 2 L) at pH -4.3 and 20 °C (van der Meer et al, 2013).…”
Section: Discussionmentioning
confidence: 95%
“…It has also been shown that the Lu-DOTATATE complex is accompanied by the presence of short-lived unstable, mono- and di-protonated (MHL, MH 2 L) complex species (van der Meer et al, 2013). These species have a dissociation rate constant of 8*10 − 5 s − 1 (MHL) & 2*10 − 4 s − 1 (MH 2 L) at pH -4.3 and 20 °C (van der Meer et al, 2013). Therefore, the presently estimated dissociation rate constant does not represent the dissociation of single species, but is rather a combination of the dissociation contribution from three different species i.e.…”
Background
In this work, a lutetium-177 (
177
Lu) production method based on the separation of nuclear isomers,
177m
Lu &
177
Lu, is reported. The
177m
Lu-
177
Lu separation is performed by combining the use of DOTA & DOTA-labelled peptide (DOTATATE) and liquid-liquid extraction.
Methods
The
177m
Lu cations were complexed with DOTA & DOTATATE and kept at 77 K for periods of time to allow
177
Lu production. The freed
177
Lu ions produced via internal conversion of
177m
Lu were then extracted in dihexyl ether using 0.01 M di-(2-ethylhexyl) phosphoric acid (DEHPA) at room temperature. The liquid-liquid extractions were performed periodically for a period up to 35 days.
Results
A maximum
177
Lu/
177m
Lu activity ratio of 3500 ± 500 was achieved with [
177m
Lu]Lu-DOTA complex, in comparison to
177
Lu/
177m
Lu activity ratios of 1086 ± 40 realized using [
177m
Lu]Lu-DOTATATE complex. The
177
Lu-
177m
Lu separation was found to be affected by the molar ratio of lutetium and DOTA. A
177
Lu/
177m
Lu activity ratio up to 3500 ± 500 was achieved with excess DOTA in comparison to
177
Lu/
177m
Lu activity ratio 1500 ± 600 obtained when lutetium and DOTA were present in molar ratio of 1:1. Further, the
177
Lu ion extraction efficiency, decreases from 95 ± 4% to 58 ± 2% in the presence of excess DOTA.
Conclusion
The reported method resulted in a
177
Lu/
177m
Lu activity ratio up to 3500 after the separation. This ratio is close to the lower end of
177
Lu/
177m
Lu activity ratios, attained currently during the direct route
177
Lu production for clinical applications (i.e. 4000–10,000). This study forms the basis for further extending the liquid-liquid extraction based
177m
Lu-
177
Lu separation in order to lead to a commercial
177m
Lu/
177
Lu radionuclide generator.
Electronic supplementary material
The online version of this article (10.1186/s41181-019-0064-5) contains supplementary material, which is available to authorized users.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.